Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City
Rhea-AI Summary
Picard Medical (NYSE American: PMI) will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 in New York City.
Patrick NJ Schnegelsberg, CEO of Picard Medical, will be available for one-on-one investor meetings; investors should contact their Canaccord Genuity sales representative to schedule a meeting with management.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PMI declined 4.53%, reflecting a moderate negative market reaction. Argus tracked a trough of -12.1% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $208M at that time.
Data tracked by StockTitan Argus on the day of publication.
TUCSON, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will attend the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum to be held on November 20, 2025, in New York, NY.
Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., will be available for one-on-one meetings with investors; to schedule a meeting, please contact your CG sale representative to set up a meeting with management.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ
When will Picard Medical (PMI) attend the Canaccord Genuity MedTech forum?
Who from Picard Medical (PMI) will meet with investors at the November 20, 2025 forum?
How do investors schedule a one-on-one meeting with Picard Medical (PMI) at the forum?
Where is the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025?
Does Picard Medical (PMI) mention a public presentation or webcast at the November 20, 2025 forum?
Which Picard Medical product or subsidiary is referenced in the November 12, 2025 notice?
